UCB’s Cimzia®, Accepted By FDA for Review



Cimzia® (certolizumab pegol) – a product of UCB – is an investigational drug for the treatment of rheumatoid arthritis (RA).

UCB’s biologics license application (BLA) for Cimzia® (certolizumab pegol) for the treatment of adult patients with active rheumatoid arthritis (RA) has recently been accepted for filing and review by the US FDA.

Cimzia® is an investigational agent. If approved, Cimzia® will be the first and only PEGylated anti-TNF (Tumor Necrosis Factor) biologic therapy available for the treatment of rheumatoid arthritis.

Cimzia® showed promise in various Phase II trials whose results were presented at the recent American College of Rheumatology (ACR) Annual Scientific Meeting.

Such clinical data were the basis of the BLA submitted to the FDA.

In these studies Cimzia®, given with methotrexate, was shown to be significantly more effective than methotrexate alone for the inhibition of joint damage progression in patients with active RA as early as 24 weeks (RAPID 1 and RAPID 2).

Cimzia® was shown to rapidly reduce the signs and symptoms of active RA with peak ACR50 and 70 responses achieved at 14 and 16 weeks. Improvement in physical function and quality of life measures were also seen for up to one year (RAPID 1).

Further, Cimzia® administered as monotherapy showed significant improvement in signs and symptoms of RA from week 1 and this benefit was maintained through week 24 (Study 011). The most commonly occurring adverse reactions, were headache, nasopharyngitis, and upper respiratory tract infections.

Reported serious adverse reactions were infections (including tuberculosis) and malignancies (including lymphoma), consistent with findings from other trials in the anti-TNF class.

Cimzia® however, is not new to the market. In September 2007, Cimzia® was approved in Switzerland for the treatment of Crohn’s disease.

Now, on top of the BLA submitted to the FDA for the treatment of adult patients with active rheumatoid arthritis (RA), UCB also has an ongoing preparation for the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for Cimzia® in the treatment of RA.

Source: UCB PR

Related Posts with Thumbnails
Print Friendly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
Can you remember what happened 90 years ago?

Since Christmas, my wife and I have spent a lot of time at the local nursing home. Not checking out...

Close